Chimeric embryos refer to cell lines composed of two or more different chromosomes in embryonic cells, usually caused by early division errors of the fertilized egg or in vitro culture operations. Whether such embryos can be transferred requires comprehensive multi-dimensional assessment
1. Transplantation feasibility assessment
Chimericratio: If abnormal cells account for less than 20% and are located in the placenta (trophoblast), they may not affect fetal development, so transplantation may be considered; if abnormal cells are more than 50% or invade the fetal development area (inner cell mass), the risk is significantly increased.
Chromosome types: There is a higher risk of chimeras involving key chromosomes such as 21st and 18th chromosomes, or sex chromosomes like 45,X/46,XY. Therefore, caution is required in these cases. Non-key chromosomal chimeras, such as those involving 1st and 19th chromosomes, are relatively safer to handle.
Patient conditions: If no whole-sex embryos are available, or if the patient is elderly or has low ovarian function, then transplantation of low-proportion chimeric embryos may be considered.

2. Transplantation risks and success rates
is lower than euploid embryos (60%-70%), but higher than completely abnormal embryos.
Risks: Increased miscarriage rates (positively correlated with the proportion of chimeric embryos). The probability of chromosomal abnormalities in the fetus is approximately 10%-30%. Diagnosis can only be made through amniocentesis during the second trimester of pregnancy.

3. Post-transplant management
Prenataldiagnosis: Amniocentesis must be performed after transplantation to rule out fetal chromosomal abnormalities.
Monitoring: Strengthen monitoring of ultrasound examinations and blood parameters during pregnancy to detect any abnormalities in placental function.

4. Future Technology Outlook

With the development of technologies such as single cell sequencing and AI prediction models, it may be possible to more accurately assess the development potential of chimera embryos in the future, and even correct abnormal cells through gene editing.
Summary: Chimeric embryo transfer requires individualized decision-making with genetic counseling and fully informed consent.
:,.For patients without other embryos to choose from, a low proportion of chimera embryos is a potential option, but requires corresponding risks and strict follow-up.